Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 1

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02252549Not ApplicableCompleted

An International Randomized Study to Compare SPIES Versus WLI

Role: lead

NCT01835977Phase 2Unknown

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Role: lead

NCT02281188Unknown

Registry for Treatment of Upper Urinary Tract Tumours

Role: lead

NCT02255890Unknown

Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device

Role: lead

NCT01180478Not ApplicableCompleted

Comparison Study of Narrow Band Imaging Versus White Light Resection in Patients With Bladder Tumors/Cancer

Role: lead

NCT03087812Completed

Durability of Flexible Ureteroscopes and Causes of Infection During Flexible Ureterorenoscopy

Role: lead

NCT01790451Phase 1Completed

Safety and Efficacy of Irreversible Electroporation in Ablation of Prostate Cancer in Humans

Role: lead

NCT02174302Completed

Ì-SPIES, Comparison of Cystoscopy Images in Four Different SPIES Modalities

Role: lead

All 8 trials loaded